Gene Therapy Trial Restores Hearing in Children Born Deaf
Similar Articles
Lab-Grown Insulin-Producing Cells Restore Blood Sugar Control in Diabetic Mice
Brain-Controlled Hearing Aid Shows Promise for Isolating Voices in Crowds
Serotonin Increase Linked to Tinnitus Symptoms in Mouse Study
Modified CAR-T Cell Therapy Shows Promising HIV Suppression in Early Trial
Elementary School Embraces Sign Language to Support Deaf Student
A clinical trial using a single gene therapy injection has restored hearing in children born deaf due to a specific genetic mutation. All ten trial participants, aged one to 24, showed measurable improvement, with the most dramatic gains seen in children between five and eight years old. The treatment, which delivers a working copy of the OTOF gene directly to the inner ear, appears to be safe with no serious adverse reactions observed.
Facts First
- All ten trial participants with congenital deafness showed measurable hearing improvement after receiving a single gene therapy injection.
- The average sound detection level improved from 106 decibels to 52 decibels within six months of treatment.
- Children aged five to eight showed the sharpest gains, with some able to have everyday conversations within months.
- No serious adverse reactions were reported during a six- to twelve-month follow-up period.
- The therapy delivers a working OTOF gene to the inner ear using a synthetic virus, addressing the root cause rather than aiding sound.
What Happened
Researchers at Karolinska Institutet published results from a trial involving ten patients with congenital deafness caused by mutations in the OTOF gene. The therapy used a synthetic adeno-associated virus (AAV) to deliver a working copy of the OTOF gene directly into the cochlea via a single injection. Every patient in the trial showed measurable improvement, with most noticing changes within one month. By six months, the average level at which participants could detect sound shifted from 106 decibels to 52 decibels. A seven-year-old girl was able to have everyday conversations with her mother four months after treatment.
Why this Matters to You
If someone in your family is affected by congenital deafness linked to an OTOF mutation, this trial represents a potential future treatment that addresses the root genetic cause rather than providing an external aid. The therapy could offer a path to natural hearing development, particularly for young children, which may improve language acquisition and social integration. For the broader public, the success of this targeted gene delivery may pave the way for similar treatments for other forms of genetic hearing loss.
What's Next
Long-term follow-up is ongoing to monitor the durability of the treatment's effects. The therapy was developed by Otovia Therapeutics Inc., which funded part of the research. While this treatment is specific to OTOF mutations, which account for a relatively small share of genetic hearing loss, the approach could inform future therapies for other genetic causes. Further trials and regulatory approvals will be needed before this therapy could become widely available.